Short answer: Inositol — most often the pairing of myo-inositol and D-chiro-inositol — is one of the most commonly discussed supplements in polycystic ovary syndrome (PCOS) and insulin-resistance care, usually cited in a 40:1 myo-to-D-chiro ratio at around 4 g of myo-inositol daily. The evidence is genuinely promising but still limited and evolving: studies suggest it may support insulin sensitivity, menstrual regularity and ovulation in some women, though the international guidelines treat it cautiously. Basic single-ratio inositol is widely sold, but where a prescriber wants a specific ratio, an adjusted dose, folate or another adjunct built in, or a clean excipient profile for a sensitive patient, a compounding pharmacy prepares that formulation to the exact specification a doctor sets. At Lynnity this is prescription-only: every preparation, supplements included, is made solely on the prescription of a registered doctor and prepared under the Ministry of Health’s Good Compounding Practice (GCP) guideline. A compounded preparation is made to order for one patient — it is not a mass-produced, MAL-registered product and cannot be bought directly, and it supports, rather than replaces, a doctor’s overall management of PCOS.
PCOS is one of the most common endocrine conditions clinics in Kuala Lumpur, Klang Valley and Singapore see in women of reproductive age, and inositol comes up in almost every conversation about it — raised by patients who have read about it, and by practitioners looking for a well-tolerated adjunct to lifestyle and standard care. This guide is written for prescribers and referring practitioners: what inositol actually is, why the myo-to-D-chiro ratio is talked about so much, what the current evidence does and does not support, and where a compounding pharmacy adds something a fixed retail tub cannot. It is orientation for clinicians, not a treatment protocol.
What inositol is — and the two forms that matter
Inositol is a sugar-alcohol the body makes and also obtains from food; it acts as a second messenger inside cells, including in the signalling pathways that insulin uses. Two of its nine forms are the ones that matter clinically: myo-inositol (MI), by far the most abundant, and D-chiro-inositol (DCI), which the body converts from myo-inositol under the influence of insulin. In simple terms, myo-inositol is associated with glucose uptake and healthy egg (oocyte) signalling, while D-chiro-inositol is associated with glycogen storage. The two are not interchangeable, and — importantly — more D-chiro-inositol is not better. This is the single idea a clinic most needs to hold onto, and it is why the ratio, rather than the raw amount, is the talking point.
Why the 40:1 ratio is talked about
In the bloodstream of healthy people, myo-inositol and D-chiro-inositol sit at roughly a 40-to-1 balance, and many formulations are built to mirror that plasma ratio. The rationale for pairing the two, rather than using either alone, is that the combination is thought to address both the insulin-signalling and the ovarian sides of the picture at once. It is worth being measured here: the 40:1 figure is the plasma ratio, and the ratio inside the ovarian follicle is different again, so 40:1 is a reasoned convention rather than a proven optimum. Some products use other ratios; the honest position is that 40:1 is the most studied and the most defensible default, but the right balance for a particular patient is a prescriber’s judgement — not a marketing claim. That judgement is exactly what a compounded preparation can express precisely.
What the evidence supports — and where it is thin
It helps to be straight with clinics about the state of the evidence. On the more encouraging side: multiple trials and meta-analyses report that myo-inositol, alone or with D-chiro-inositol, may improve markers of insulin resistance and can be associated with more regular cycles and improved ovulation in some women with PCOS, and it is consistently well tolerated with a mild side-effect profile. On the more cautious side: the 2023 update of the International Evidence-based PCOS Guideline reviewed inositol and concluded that the certainty of evidence remains low, that it cannot yet be recommended over first-line options, and that decisions should be shared with the patient in light of that uncertainty. Trial designs, doses and ratios also vary widely, which makes the literature harder to pool.
The defensible framing for a clinic is therefore this: inositol is a reasonable, low-risk adjunct that many patients tolerate well and some respond to, used alongside — never instead of — a doctor’s assessment and the established pillars of PCOS care such as lifestyle and, where indicated, prescribed medicines. It is not a cure for PCOS, it does not work for everyone, and it should sit inside a monitored plan rather than be treated as a standalone fix.
| Component | General profile (evidence-hedged) | Practitioner note |
|---|---|---|
| Myo-inositol (MI) | The abundant form; associated with insulin signalling and oocyte quality. Usual studied amount around 4 g/day. | The backbone of most PCOS formulations. |
| D-chiro-inositol (DCI) | Insulin-converted form linked to glycogen storage; small amounts only. More is not better. | Typically a small fraction of the myo dose — hence the ratio focus. |
| 40:1 MI:DCI ratio | Mirrors the healthy plasma balance; the most studied and defensible default. | A reasoned convention, not a proven optimum — prescriber sets the ratio for the patient. |
| Folate / other adjuncts | Folate is often paired in fertility contexts; other adjuncts are sometimes added on clinical grounds. | Adjuncts are a prescriber decision, built in only where the doctor directs. |
Where compounding adds value
The exact ratio and dose — set by the prescriber
A retail tub commits the patient to whatever single ratio and strength a manufacturer chose to sell. A compounded preparation is made to the prescription, so a doctor can specify the myo-to-D-chiro ratio and the daily amount they want for that patient — including a lower, gentler starting dose or a defined step-up — rather than approximating with a fixed off-the-shelf product.
Adjuncts combined into one preparation
Where a prescriber wants folate, or another adjunct they have chosen on clinical grounds, prepared together with inositol in a single daily dose, compounding can build that to the doctor’s specification — or deliberately keep components separate where the clinical picture calls for it. The judgement stays with the prescriber; the pharmacy prepares to it, and flags any combination it would not recommend.
Excipient-free and allergen-aware preparation
Because the pharmacy builds from raw actives, a prescription can request inositol in a base without a particular sweetener, dye, filler or allergen a sensitive patient reacts to. This overlaps with the excipient-free and allergen-aware compounding many clinics already use for patients with multiple sensitivities.
Delivery form and palatability
Inositol at effective daily amounts is a relatively large dose, and many patients dislike the volume of powder or the number of capsules involved. A compounded preparation can be worked into a form the patient is more likely to keep taking — a measured powder, a defined capsule count, or a more palatable presentation — which matters, because a supplement only helps if it is actually taken as directed.
Consolidation — with honest limits
Clinics sometimes ask to fold inositol into a broader personalised formulation. It combines reasonably with several nutrients, but not with everything, and dose volume sets real limits on what will fit in one preparation. Where consolidation is requested, the pharmacist checks compatibility and dose feasibility before preparing, and will flag where an ingredient is better kept separate. Honest limits here protect the patient, not just the preparation.
A specific caution: fertility and pregnancy
Inositol is frequently discussed in the context of fertility, IVF support and early pregnancy, which is precisely why prescriber oversight matters so much here. Any use around conception or pregnancy — including the choice of adjuncts such as folate and their doses — is a decision for the treating doctor, made with the individual patient, and monitored accordingly. A compounding pharmacy prepares to that prescription; it does not advise patients on whether or how to use inositol while trying to conceive or during pregnancy. Practitioners should frame it the same way for their patients.
The prescribing and referral workflow
A personalised, compounded inositol preparation follows the same disciplined route as any compounded preparation at Lynnity, and it always starts with a prescriber — never with the pharmacy.
A registered doctor assesses the patient — typically as part of a broader PCOS or metabolic workup — decides the myo-to-D-chiro ratio, the dose, any adjunct and the delivery form, and writes a prescription specifying the actives, the strengths, the form, the quantity and the directions. The clinic sends it to the pharmacy; Lynnity confirms feasibility, prepares the preparation under GCP, and dispenses it back to the patient. Any change to ratio or dose goes back through the same loop as a fresh prescription, which is also how review and monitoring are built in.
A non-prescribing practitioner — a dietitian or nutritionist, say — who thinks a patient may benefit refers them, with those notes, to a registered doctor. The doctor reviews, confirms, decides and writes the prescription; only then does the pharmacy prepare it. A compounding pharmacy cannot supply a compounded supplement on a non-prescriber’s request alone, and no reputable one will imply otherwise. There is no “no prescription needed” route at Lynnity.
Both patterns share the same anchor: a registered doctor’s prescription sits at the centre, and the pharmacy prepares strictly to it under Good Compounding Practice (GCP) — the Ministry of Health guideline covering how compounded preparations are made, checked, labelled and documented. GCP is the correct standard for pharmacy compounding, and it is distinct from GMP, which governs mass manufacturing. Lynnity is a compounding pharmacy, not a manufacturer and not a supplement brand: it does not mass-produce or contract-manufacture products, and it prepares only what a prescriber specifies for a named patient.
A note for Singapore clinics
Clinics in Singapore sometimes ask whether a Malaysian compounding pharmacy can prepare a personalised inositol formulation against a Singapore prescription. Cross-border supply of compounded, prescription-only preparations is governed by the receiving country’s own rules, which differ from Malaysia’s. Confirm the position with your own regulator before assuming a preparation can cross the border, and treat this article as general orientation rather than a compliance opinion.
Frequently asked questions
What is the difference between myo-inositol and D-chiro-inositol?
They are two forms of inositol with different roles: myo-inositol is the abundant form linked to insulin signalling and oocyte quality, while D-chiro-inositol is converted from it under insulin and is linked to glycogen storage. They are not interchangeable, and more D-chiro-inositol is not better — which is why formulations focus on the ratio between them rather than the raw amount.
Why is a 40:1 ratio used for PCOS?
A roughly 40-to-1 balance of myo- to D-chiro-inositol mirrors the ratio found in healthy human plasma, so many formulations are built to match it. It is the most studied and defensible default rather than a proven optimum, and the right ratio for a particular patient is a prescriber’s decision.
Does inositol actually work for PCOS?
Studies suggest myo-inositol, alone or with D-chiro-inositol, may improve markers of insulin resistance and support more regular cycles and ovulation in some women, and it is generally well tolerated. However, the 2023 international PCOS guideline judged the certainty of evidence to be low and did not place it above first-line options, so it is best viewed as a low-risk adjunct within a doctor’s overall plan, not a cure.
Why would a clinic compound inositol instead of using a retail product?
Compounding lets a prescriber set the exact myo-to-D-chiro ratio and dose for the patient, build in folate or another adjunct they have chosen, leave out a sweetener, dye or allergen a sensitive patient reacts to, and prepare a more palatable or manageable form — flexibility a fixed retail tub cannot offer.
Is inositol safe to take in pregnancy or when trying to conceive?
Inositol is often discussed around fertility and early pregnancy, but any use in that context — including adjuncts and doses — is a decision for the treating doctor, made with the individual patient and monitored. A compounding pharmacy prepares to that prescription and does not advise patients on use during conception or pregnancy.
Do compounded inositol formulations still need a prescription?
Yes. Every Lynnity preparation, supplements included, is made solely on the prescription of a registered doctor. There is no direct-purchase or “no prescription needed” route. A referring practitioner sends the patient to a doctor, who assesses and prescribes.
We’re a clinic in KL — how do we start prescribing a personalised inositol formulation through Lynnity?
Contact us through lynnitypharma.com and ask to speak with a pharmacist. We can talk through the achievable ratios and doses, adjunct options such as folate, excipient-free options for sensitive patients, palatable delivery forms and beyond-use dating before your first prescription is sent.
Reviewed by the Lynnity pharmacy team — registered pharmacists compounding to Good Compounding Practice (GCP) in Kuala Lumpur.
This article is general information for healthcare practitioners and is not medical advice. It does not diagnose, treat or recommend therapy for any condition. All Lynnity preparations, supplements included, require a prescription from a registered doctor.